<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001038.v1.p1" parentStudy="phs001038.v1.p1" createDate="2015-12-03" modDate="2016-02-18">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Timothy A. Chan, MD, PhD, Vice Chair, Department of Radiation Oncology</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Stephen B. Baylin, MD</td><td>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Jedd D. Wolchok, MD, PhD</td><td>Memorial Sloan Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Katherine B. Chiapinelli, PhD</td><td>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Reiner Strick, PhD</td><td>Laboratory for Molecular Medicine, University-Clinic Erlangen, Erlangen, Germany</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>DNA Methylation Inhibitors in Immunotherapy</StudyNameEntrez>
	<StudyNameReportPage>Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway and re-expression of epigenetically silenced endogenous retrovirus. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b>Inclusion:</b> patients with melanoma who were treated with ipilimumab or tremelimumab</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="26317466"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Melanoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Timothy A. Chan, MD, PhD, Vice Chair, Department of Radiation Oncology</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Stephen B. Baylin, MD</AttName>
			<Institution>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Jedd D. Wolchok, MD, PhD</AttName>
			<Institution>Memorial Sloan Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Katherine B. Chiapinelli, PhD</AttName>
			<Institution>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Reiner Strick, PhD</AttName>
			<Institution>Laboratory for Molecular Medicine, University-Clinic Erlangen, Erlangen, Germany</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>CA058184</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Epigenetic Dream Team</AttName>
			<Institution>Stand Up to Cancer-Cancer Research Institute, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>The Samuel Waxman Cancer Research Foundation</AttName>
			<Institution>Samuel Waxman Cancer Research, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</AttName>
			<Institution>USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Department of Defense (DOD) Teal Award BC031272</AttName>
			<Institution>Department of Defense, US Army Medical Research and Materiel Command, Fort Detrick, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>The Pershing Square Foundation and the Sohn Conference Foundation</AttName>
			<Institution>Pershing Square Sohn Cancer Research Alliance, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>STARR Cancer Consortium</AttName>
			<Institution>USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>The Ludwig Foundation</AttName>
			<Institution>USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>F32CA183214</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>The German Cancer Aid (Deutsche Krebshilfe 108215)</AttName>
			<Institution>German Cancer Aid, Bonn, Germany</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-PUB-NPU-MDS" longName="Health/Medical/Biomedical (PUB, NPU, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001038.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001038.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001038.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical (PUB, NPU, MDS)</ConsentName>
        <ConsentAbbrev>HMB-PUB-NPU-MDS</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor agrees to make results of studies using the data available to the larger scientific community.
Use of the data is limited to not-for-profit organizations.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
